Stock Track | Labcorp Soars 9.80% in Pre-market on Strong Q1 Earnings Beat and Raised 2026 Guidance

Stock Track

04/30

Labcorp Holdings Inc's stock surged 9.80% in pre-market trading following the release of its first-quarter 2026 financial results that exceeded analyst expectations and an upward revision of its full-year outlook.

The company reported adjusted earnings per share of $4.25 for Q1 2026, beating consensus estimates of approximately $4.09 to $4.11 and representing a 10.6% increase from the same period last year. Revenue rose 5.8% year-over-year to $3.54 billion, also surpassing analyst forecasts of around $3.50 to $3.51 billion.

Labcorp raised its full-year 2026 guidance, now expecting adjusted EPS in the range of $17.70 to $18.35 and revenue between $14.65 billion and $14.80 billion. The company cited organic growth, continued momentum across its Diagnostics and Central Laboratory businesses, and strategic initiatives including expansion in specialty diagnostics and new collaborations as drivers of its strong performance.

免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。

熱議股票

{"basename":"/hant","ssrTDKData":{"titleTemplate":"%s - 老虎證券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎證券,老虎證券開戶,老虎券商,老虎證券官網,老虎證券app,tigertrade老虎證券,股票,炒股,新加坡股票交易平臺,投資,投資理財","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.0a0bd8dc.png","ogUrl":"https://www.itiger.com/hant/news/1185853360"},"companyName":"老虎證券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"1185853360\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/1185853360?lang=zh_TW&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-04-30 19:32","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1185853360","market":"hk","top_or_hot":-1,"title":"Stock Track | Labcorp Soars 9.80% in Pre-market on Strong Q1 Earnings Beat and Raised 2026 Guidance","media":"Stock Track","content":"<p>Labcorp Holdings Inc's stock surged 9.80% in pre-market trading following the release of its first-quarter 2026 financial results that exceeded analyst expectations and an upward revision of its full-year outlook.</p><p>The company reported adjusted earnings per share of $4.25 for Q1 2026, beating consensus estimates of approximately $4.09 to $4.11 and representing a 10.6% increase from the same period last year. Revenue rose 5.8% year-over-year to $3.54 billion, also surpassing analyst forecasts of around $3.50 to $3.51 billion.</p><p>Labcorp raised its full-year 2026 guidance, now expecting adjusted EPS in the range of $17.70 to $18.35 and revenue between $14.65 billion and $14.80 billion. The company cited organic growth, continued momentum across its Diagnostics and Central Laboratory businesses, and strategic initiatives including expansion in specialty diagnostics and new collaborations as drivers of its strong performance.</p>","source":"ai_movement_en","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Stock Track | Labcorp Soars 9.80% in Pre-market on Strong Q1 Earnings Beat and Raised 2026 Guidance</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 12.5px; color: #7E829C; margin: 0;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nStock Track | Labcorp Soars 9.80% in Pre-market on Strong Q1 Earnings Beat and Raised 2026 Guidance\n</h2>\n<h4 class=\"meta\">\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1086803395\">\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/a81accab1e7ee4144dc051f71903a390);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Stock Track </p>\n<p class=\"h-time smaller\">2026-04-30 19:32</p>\n</div>\n</a>\n</h4>\n</header>\n<article>\n<p>Labcorp Holdings Inc's stock surged 9.80% in pre-market trading following the release of its first-quarter 2026 financial results that exceeded analyst expectations and an upward revision of its full-year outlook.</p><p>The company reported adjusted earnings per share of $4.25 for Q1 2026, beating consensus estimates of approximately $4.09 to $4.11 and representing a 10.6% increase from the same period last year. Revenue rose 5.8% year-over-year to $3.54 billion, also surpassing analyst forecasts of around $3.50 to $3.51 billion.</p><p>Labcorp raised its full-year 2026 guidance, now expecting adjusted EPS in the range of $17.70 to $18.35 and revenue between $14.65 billion and $14.80 billion. The company cited organic growth, continued momentum across its Diagnostics and Central Laboratory businesses, and strategic initiatives including expansion in specialty diagnostics and new collaborations as drivers of its strong performance.</p>\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"LH","symbol_name":"徠博科","start_time":0,"source_url":"","article_id":"1185853360","we_media_id":"1086803395","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1185853360","pubTimestamp":1777548779,"columns":[],"sourceInfo":{"source_id":"ai_movement_en","name":"Stock Track"},"weMediaInfo":{"media_name":"Stock Track","introduction":"Track stock‘s movements and relevant news","home_visible":1,"id":"1086803395","head_image":"https://static.tigerbbs.com/a81accab1e7ee4144dc051f71903a390"},"summary":"Labcorp Holdings Inc's stock surged 9.80% in pre-market trading following the release of its first-quarter 2026 financial results that exceeded analyst expectations and an upward revision of its...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"LH":"徕博科"},"translate_title":"股票追踪|Labcorp盘前飙升9.80%，第一季度盈利强劲，并上调2026年指引","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"LH":1},"content_text":"Labcorp Holdings Inc's stock surged 9.80% in pre-market trading following the release of its first-quarter 2026 financial results that exceeded analyst expectations and an upward revision of its full-year outlook.The company reported adjusted earnings per share of $4.25 for Q1 2026, beating consensus estimates of approximately $4.09 to $4.11 and representing a 10.6% increase from the same period last year. Revenue rose 5.8% year-over-year to $3.54 billion, also surpassing analyst forecasts of around $3.50 to $3.51 billion.Labcorp raised its full-year 2026 guidance, now expecting adjusted EPS in the range of $17.70 to $18.35 and revenue between $14.65 billion and $14.80 billion. The company cited organic growth, continued momentum across its Diagnostics and Central Laboratory businesses, and strategic initiatives including expansion in specialty diagnostics and new collaborations as drivers of its strong performance.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":true,"editions":null,"column":"","sentiment":"2","news_tag":"movement","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"}}}